Pancreatic Cancer Diagnostics Market By type of test (Blood Tests, Biopsy, Biological Markers), by type of cancer (Adenocarcinoma, Squamous carcinoma, Adenosquamous carcinoma), by End User (Hospitals, Oncology Institutes, Diagnostic Centres), and Geography.


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Global Pancreatic Cancer Diagnostics Market was valued at approximately USD 3,562.51 million in 2020 and is expected to witness a revenue of USD 5,999.78 million in 2027, with a CAGR of 8.9% over the forecast period. Pancreatic cancer will begin in tissues of pancreas. Pancreas secretes enzymes which helps in the digestion and manage blood sugar levels. pancreatic cancer diagnostics market rapidly spreads to the nearby organs. Often it can be diagnosed at early stages in people with pancreatic cyst or family history of pancreatic cancer. Most common sign of pancreatic cancer is diabetes which occurs along with loss of weight, pain in the upper abdomen and that spreads to the back. This development can be attributed to patients' desire for comprehensive therapy and the availability of enhanced instruments and knowledge. Due to an increase in the consumption of alcohol and cigarettes, as well as changes in lifestyle, the market for pancreatic cancer diagnostics is growing. Furthermore, widespread use of high-cost medications such as Abraxane injection and Gemzar to treat pancreatic cancer boosts the market. Technologies for timely diagnosis of pancreatic cancer are yet to develop at a full stretch which may results in early diagnosis of advanced stage of pancreatic cancer and can provide rightful treatment. Moreover, major players are getting collaborated with government and other social responsible agencies to improve the patient accessibility and affordability towards the treatments and diagnosis. For example, Illumina, Inc. has launched a venture called GRAIL along with Billgates and Jeff Bezos as investors with $100 Mn to focus on the blood based cancer screening for early and timely diagnosis of the common tumours through simple laboratory tests.

Global Pancreatic Cancer Diagnostics Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

–  Europe
Pancreatic Cancer Diagnostics Market Dynamics

Increasing prevalence of pancreatic cancer is expected to accelerate the growth of pancreatic cancer diagnostics market. According World Cancer Research Fund International, pancreatic cancer is the 12th most common cancer, and it has estimated that about 3, 38,000 cases were diagnosed with pancreatic cancer in 2012. Moreover, Growing awareness and concern about the disease, increase in healthcare expenditure, technological advancements and innovation of new products, large number of unmet needs related to disease are the few factors which are expected to fuel the growth of pancreatic cancer diagnostics market. However, limited options for treatment, inaccurate and inadequate results of the diagnosis, high cost associated with the tests are major restraints of pancreatic cancer diagnostics market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Pancreatic Cancer Diagnostics Market Segmentation

By type of test
  • Blood Tests
  • Biopsy
  • Biological Markers
By type of cancer
  • Adenocarcinoma
  • Squamous carcinoma
  • Adenosquamous carcinoma
by End User
  • Hospitals
  • Oncology Institutes
  • Diagnostic Centres
By Geography
North America
  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe
  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific
Latin America
  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America
Middle East and Africa (MEA)
  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

[urltag url='request-table-of-content']

  • Ambry Genetics (U.S)
  • Abbott Laboratories, Inc.(U.S)
  • AstraZeneca plc (U.K)
  • Eli Lilly and Company(U.S.)
  • BioMeriux SA (France)
  • Illumina, Inc.(U.S)
  • Genoptix, Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Pfizer, Inc. (U.S.)
  • GlaxoSmithKline plc (UK)
  • Amgen, Inc.(U.S)
  • Celgene corporation (U.S)
  • Novartis AG (Switzerland)